A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations

被引:68
作者
Kreppel, F [1 ]
Biermann, V [1 ]
Kochanek, S [1 ]
Schiedner, G [1 ]
机构
[1] Univ Cologne, Ctr Mol Med ZMMK, D-50931 Cologne, Germany
关键词
D O I
10.1089/104303402320138934
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
High-capacity adenoviral (HC-Ad) vectors are devoid of all viral genes. Therefore, these vectors feature reduced toxicity, immunogenicity, and increased capacity for foreign DNA. HC-Ad vectors are produced in E1-transformed cell lines in the presence of an E1-deleted helper virus that provides in trans all viral functions necessary for vector production. By cre/loxP- or FLPe/Frt-mediated recombination the packaging signal of the helper virus is excised during vector production resulting in nonpackagable helper virus genomes. Although recombinase-mediated excision of the packaging signal from the helper virus genome is highly efficient, a small number of helper virus genomes with retained packaging signals are still packaged into capsids. For clinical trials, HC-Ad vector preparations have to be characterized accurately with respect to the number of (1) total HC-Ad vector particles, (2) infectious HC-Ad vector particles, and (3) the number of contaminating helper virus particles. We describe a fast and versatile DNA-based biologic assay for determination of these three parameters by standard laboratory methods. This assay is a useful tool for determining bioactivity data of adenoviral vector preparations and, importantly, allows their comparison among different studies.
引用
收藏
页码:1151 / 1156
页数:6
相关论文
共 22 条
  • [1] Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis
    Aurisicchio, L
    Delmastro, P
    Salucci, V
    Paz, OG
    Rovere, P
    Ciliberto, G
    La Monica, N
    Palombo, F
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (10) : 4816 - 4823
  • [2] Targeting of high-capacity adenoviral vectors
    Biermann, V
    Volpers, C
    Hussmann, S
    Stock, A
    Kewes, H
    Schiedner, G
    Herrmann, A
    Kochanek, S
    [J]. HUMAN GENE THERAPY, 2001, 12 (14) : 1757 - 1769
  • [3] In vivo dose threshold effect of adenovirus-mediated Factor VIII cone therapy in hemophiliac mice
    Bristol, JA
    Shirley, P
    Idamakanti, N
    Kaleko, M
    Connelly, S
    [J]. MOLECULAR THERAPY, 2000, 2 (03) : 223 - 232
  • [4] DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle
    Chen, HH
    Mack, LM
    Choi, SY
    Ontell, M
    Kochanek, S
    Clemens, PR
    [J]. HUMAN GENE THERAPY, 1999, 10 (03) : 365 - 373
  • [5] STEPWISE DISMANTLING OF ADENOVIRUS-2 DURING ENTRY INTO CELLS
    GREBER, UF
    WILLETTS, M
    WEBSTER, P
    HELENIUS, A
    [J]. CELL, 1993, 75 (03) : 477 - 486
  • [6] High-capacity adenoviral vectors for gene transfer and somatic gene therapy
    Kochanek, S
    [J]. HUMAN GENE THERAPY, 1999, 10 (15) : 2451 - 2459
  • [7] LAWRENCE WILLIAM C., 1967, J VIROL, V1, P851
  • [8] Is green fluorescent protein toxic to the living cells?
    Liu, HS
    Jan, MS
    Chou, CK
    Chen, PH
    Ke, NJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 260 (03) : 712 - 717
  • [9] Rapid determination of adenoviral vector titers by quantitative real-time PCR
    Ma, L
    Bluyssen, HAR
    De Raeymaeker, M
    Laurysens, V
    van der Beek, N
    Pavliska, H
    van Zonneveld, AJ
    Tomme, P
    van Es, HHG
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2001, 93 (1-2) : 181 - 188
  • [10] Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector
    Maione, D
    Wiznerowicz, M
    Delmastro, P
    Cortese, R
    Ciliberto, G
    La Monica, N
    Savino, R
    [J]. HUMAN GENE THERAPY, 2000, 11 (06) : 859 - 868